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MaLeft ventricular assist devices are becoming an increasingly prevalent therapy for patients with Stage D heart failure with
reduced ejection fraction. Technological advances have improved the durability of these devices and have signiﬁcantly
lengthened survival in these patients. Quality of life is also improved, although adverse events related to device therapy
remain common. Nevertheless, with the continuing organ donor shortage for cardiac transplantation, left ventricular
assist devices are frequently serving as a substitute for transplant, particularly in the elderly patient. (J Am Coll Cardiol
2015;65:2542–55) © 2015 by the American College of Cardiology Foundation.H eart failure (HF) incidence and prevalenceis increasing at epidemic proportions. Thisrise in HF incidence is, in part, due to the
success cardiologists have made in salvaging patients
who have acute myocardial infarctions. Improved
survival in patients with HF and the aging of the pop-
ulation has contributed to the increasing prevalence
of HF (1–3). In the United States alone, 5.8 million
Americans have HF. The incidence is estimated at
650,000 new cases annually, with over a million
annual hospital admissions. More than 300,000
deaths/year are attributed to HF, and the annual
cost to manage these patients is close to $40 billion.
Approximately 50% of the HF population has heart
failure with reduced ejection fraction (HFrEF). In
this subset of patients, probably 10% have advanced
symptoms (New York Heart Association [NYHA] func-
tional class IIIB to IV), yielding an estimated cohort of
approximately 200,000 to 250,000 patients (1–3) who
will be the focus of our review.
THERAPEUTIC IMPROVEMENTS IN HFrEF
MEDICAL THERAPIES. Many advances have been
made in the management of HFrEF, notably with the
use of neurohormonal antagonists. These agentsm the Department of Medicine, Columbia University, New York, New Yor
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of life in patients with HFrEF. However, since this
therapy was developed in the 1980s and 1990s,
newer pharmacological therapies have been few (4).
Treatment with the Food and Drug Administration
(FDA)–approved selective sinus-node inhibitor ivab-
radine reduces hospital admission for worsening HF
(5). More recently, LCZ696, which combines angio-
tensin II inhibition with a neprilysin inhibitor,
has been demonstrated to hold promise for HFrEF
patients (6).
SURGICAL THERAPIES. The greatest advances in
HFrEF therapy over the last decade have been surgi-
cal approaches (7–9). Biventricular pacing has resul-
ted in improved survival, reverse remodeling, and
improved quality of life (10). For patients with re-
fractory HFrEF (i.e., Stage D), progress in cardiac
replacement therapies has been substantial. Howev-
er, palliation with continuous intravenous (IV) ino-
tropes remains the only therapeutic option for many
Stage D HFrEF patients, as cardiac replacement
therapies with allografts or devices have been offered
only to a small subset of these patients. A therapeutic
algorithm for Stage D HFrEF is shown in the Central
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AB BR E V I A T I O N S
AND ACRONYM S
BTT = bridge to transplant
CF = continuous ﬂow
DT = destination therapy
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
LVAD = left ventricular assist
device
MELD = Model for End-Stage
Liver Disease
NYHA = New York Heart
Association
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2543eligibility for cardiac transplantation, followed by
assessment for destination mechanical support, and
eventually, palliation. Indeed, in the 2013 Interna-
tional Society of Heart Lung Transplant guidelines for
use of mechanical devices, the initial question asked
is whether the patient is to be considered a transplant
candidate (11). With the rapid advances in mechanical
circulatory support, this algorithm may be revised in
the near future such that the initial question is eligi-
bility for destination therapy (DT), followed by heart
transplantation candidacy and palliation (Central
Illustration).
HEART TRANSPLANTATION VERSUS
LEFT VENTRICULAR ASSIST DEVICE
IN ADVANCED HFrEF
Stage D HFrEF patients are typically referred to cardiac
transplant centers, where they undergo an extensive
evaluation to determine their candidacy. Optimiza-
tion of the medical regimen and consideration for
revascularization or other standard therapies are
assessed. Signiﬁcant comorbidities that could be life-
threatening at the time of transplant surgery or post-
transplant are carefully excluded before patients are
accepted as transplant candidates (12). The short- and
long-term outcomes following cardiac transplantation
have been exceptional, with a median survival of 10.7
years and survival conditional on surviving to 1 year
after transplant of 13.6 years (13). Quality of life has
greatly improved as immunosuppressive agents have
become more targeted for the rejection process. This
therapeutic success has resulted in a glut of patients
awaiting this life-saving therapy.
THE CHRONIC LIMITATION OF ORGAN AVAILABILITY.
In the United States, 3,990 patients are currently listed
for heart transplant (14–16). The medical urgency of
patients listed has steadily increased, with the ma-
jority of those now registered for cardiac transplant
requiring inotropic or mechanical support. The major
limitation to the growth of cardiac transplant has been
the limited donor supply. Despite many campaigns to
increase donor volume by local or federal agencies, the
donor supply has remained ﬂat and is limited to
approximately 2,500 hearts annually in the United
States. Currently, warm preservation devices, such
as the Organ Care System (Transmedics, Amherst,
Massachusetts), which provides a clinical platform
for ex vivo human heart perfusion, offer hope for
increased numbers of potential donor organs. This
device may provide donors beyond the current
geographic limit imposed with cold preservation
techniques and/or identify viable donors with
clinical characteristics that ordinarily would precludetransplant in the absence of a metabolic
assessment (17). The recently completed
PROCEED II (Randomized Study of Organ Care
System Cardiac for Preservation of Donated
Hearts for Eventual Transplantation) trial (17)
demonstrated noninferiority of ex vivo pres-
ervation to cold ischemia in 130 transplant
recipients undergoing transplant with stan-
dard donors. Three cases of heart transplant
using organs from after cardiac death were
reported in Australia using this organ preser-
vation system (18). Nevertheless, despite the
hope for more usable organs, the donor supply
remains ﬂat; clearly transplant is not the so-
lution for the estimated 250,000 patients
with advanced HFrEF who could beneﬁt from car-
diac replacement therapy. Fortunately, concomitant
with the improvement in therapy for heart trans-
plantation, mechanical assist devices to support pa-
tients with end-stage HFrEF have continued to evolve.
More and more transplant candidates are requiring
mechanical support as they wait for an acceptable or-
gan. In 2000, the International Society for Heart
Transplantation reported that 19.1% of transplant re-
cipients were mechanically supported; this number
increased to 41.0% in 2012 (13). Left ventricular assist
device (LVAD) support is typically offered to trans-
plant candidates who are developing end-organ dam-
age despite maximal medical therapy, including
inotropic support, or to those candidates who are
inotrope-dependent with an anticipated long waitlist
time (i.e., large size and/or blood type O recipients).
These categories correspond to the Interagency Reg-
istry for Mechanically Assisted Circulatory Support
(INTERMACS) levels 1 to 3. The INTERMACS is a North
American registry established in 2005 that collects
clinical data for patients receiving mechanical circu-
latory support device therapy to treat advanced HF.
The INTERMACS scale assigns patients with advanced
HF into 7 levels according to hemodynamic proﬁle
and functional capacity (Figure 1). Ventricular support
devices offer improved survival to transplant with
excellent quality of life. However, implantation of the
LVAD is another surgical procedure with associated
risks, such as stroke, infection, bleeding, and sensiti-
zation, that may prolong the time to ﬁnding a suitable
organ and, in some cases, may preclude transplant.
PATIENT SELECTION FOR HEART TRANSPLANT
VERSUS LVAD. In patients with cardiogenic shock or
post-cardiotomy syndrome, many short-term me-
chanical devices provide biventricular support. For
chronic patients with Stage D HFrEF who are not
transplant candidates, the only mechanical device
FIGURE 1 INTERMACS Scale for Classifying Patients With Advanced HF
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Percent of implants by INTERMACS proﬁle. Current U.S. Food and Drug Administration (FDA) approval status and acceptance in the medical
community. Modiﬁed with permission from Estep et al (48,76). HF ¼ heart failure; INTERMACS ¼ Interagency Registry for Mechanically
Assisted Circulatory Support; NYHA ¼ New York Heart Association.
CENTRAL ILLUSTRATION LVAD Versus Transplant: Present and Future for Treating Stage D HF
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(Left) Current and (right) future proposed algorithms for treatment of Stage D HFrEF. DT ¼ destination therapy; HFrEF ¼ heart failure with reduced ejection fraction;
IV ¼ intravenous; LVAD ¼ left ventricular assist device; LVEF ¼ left ventricular ejection fraction; VO2 ¼ oxygen consumption.
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TABLE 1 Center-Speciﬁc Differences in Exclusion Criteria for Cardiac Transplant
Versus Destination LVADs
Cardiac Transplant LVAD
Body size None BSA <1.2 m2
Age, yrs >65–72 None; oldest reported
88 yrs of age
PVR, Wood Units >3 >8
RV function None RVSWI <250 mm Hg  ml/m2
Urgent situation Yes No
Comorbidities
Malignancy <5-year disease-free Chemotherapy non-completed
Renal Creatinine >2.5 mg/dl Creatinine >3 mg/dl
Pulmonary Mild to moderate Moderate to severe
Obesity BMI >30 kg/m2 BMI >45 kg/m2
Intolerance to anticoagulation No Yes
Restrictive CM No Yes
BMI ¼ body mass index; BSA ¼ body surface area; CM ¼ cardiomyopathy; LVAD ¼ left ventricular assist device;
PVR ¼ pulmonary vascular resistance; RV ¼ right ventricle; RVSWI ¼ right ventricular stroke work index.
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long-term LVADs in this patient population.
The criteria for implantation of an LVAD as DT as
outlined by the Centers for Medicare and Medicaid
Services, are as follows and are derived from the
HeartMate I (REMATCH [Randomized Evaluation of
Mechanical Assistance for the Treatment of Conges-
tive Heart Failure] [19]) and HeartMate II DT trials (7):
 Patients with NYHA functional class IV symptoms
who have failed to respond to optimal medical
management, including angiotensin-converting
enzyme inhibitors or beta-blockers, for at least
45 of the past 60 days, or have been intra-aortic
balloon pump-dependent for 7 days or IV inotrope-
dependent for 14 days;
 Left ventricular ejection fraction <25%; and
 Functional limitation with a peak oxygen con-
sumption <14 ml/kg/min, unless on an intra-aortic
balloon pump, IV inotropes, or physically unable
to perform the exercise test.
Separation of LVAD patients into bridge to trans-
plant (BTT) and DT populations has been problematic.
During their acute illness, many patients may fall into
a gray zone with comorbidities that reverse over time.
These patients are frequently categorized as “bridge
to decision.” In an attempt to normalize end-organ
function that currently precludes long-term cardiac
replacement therapies, these patients are often sup-
ported using extracorporeal membrane oxygenation
or short-term single or biventricular assist devices.
Selection criteria for DT are less rigid, in some
respects, than for transplant candidacy. Table 1 con-
trasts the key exclusion criteria used in our center
for heart transplant and DT candidates.
The presence of certain comorbidities, such as a
recent malignancy and elevated pulmonary vascular
resistance, may initially disqualify patients from
transplant listing, as cancer is more likely to recur
during immunosuppression and right HF may occur
when the allograft is exposed acutely to severe pul-
monary hypertension post-transplant. Patients with
signiﬁcant end-organ dysfunction, such as renal and
liver insufﬁciency, may eventually be reconsidered
for transplant if the end-organ function subsequently
improves.
Although an elevated pulmonary vascular resis-
tance may not exclude a patient from LVAD implan-
tation, screening for potential right HF is much more
rigorous, as no approved chronic right ventricular
support is currently available. Patients with severe
right ventricular failure may not qualify for LVAD
support and, in any case, are likely to require
prolonged temporary mechanical right ventricularsupport and/or inotropes post-operatively. Prediction
models, hemodynamic parameters, and echocardio-
graphic measurements are used to assess right
ventricular function before LVAD implantation.
A prediction score for post-operative right ventricular
failure developed by the University of Michigan
group incorporates the following variables: use of
vasopressors, aspartate aminotransferase, bilirubin,
and creatinine levels (20). Other investigators have
focused on hemodynamic parameters, such as right
ventricular stroke work index #0.25 mm Hg  l/m2
(21), the ratio of right atrial pressure to pulmonary
capillary wedge pressure >0.63, and right atrial
pressure >15 mm Hg (22). Other clinicians have
emphasized echocardiographic indexes, such as
severity of tricuspid regurgitation (23), right to left
end-diastolic dimension >0.72 (24), and right ven-
tricular free-wall strain (25). However, there are no
absolute prediction criteria for the development of
intractable right HF while on LVAD support in the
short or the long term (11,20–22,26–28).
In contrast, LVAD support is an excellent option for
those HFrEF patients with high pulmonary vascular
resistance rejected for heart transplant in the setting
of adequate right ventricular function (29–31). Fre-
quently, implantation of the device will allow the
vascular resistance to decline and allow these pa-
tients to become transplant-eligible (32,33).
Unlike heart transplantation, those HFrEF patients
with intractable angina or intractable ventricular
tachycardia are not device candidates, except in the
setting of chronic severe HF symptoms. Due to their
small ventricular cavities and frequently normal
ejection fractions, patients with restrictive cardio-
myopathies are also not LVAD candidates.
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for both transplant and mechanical assist device pa-
tients, but it is more imperative for device candi-
dates, who may need immediate assistance at home
in the event of a serious device alarm.
Age is a key criterion for acceptance for heart
transplant that has generated much debate. Some
centers will accept candidates in the seventh decade
of life, whereas other centers are more conservative
(34–36). Results of outcomes of heart transplant
in elderly patients have been mixed, whereas out-
comes of destination LVADs in this patient popula-
tion have improved. However, no study has
prospectively compared heart transplant with
LVAD-DT in elderly patients. Realistically, whether a
scarce resource, such as a cardiac allograft, should
be used in elderly patients is unclear. With the
excellent long-term survival of allografts, the organ
can very well outlast the recipient; thus, we may be
using a scarce resource for a patient group that may
not reap all of its beneﬁts. In reports of alternate list
heart transplant candidates, many over 65 years of
age who received extended donors, these recipients
frequently died, not from cardiac problems, but from
comorbidities or the development of new, unforeseen
medical problems. The intense immunosuppression
needed at the time of transplant can unmask or trigger
malignancies. At our center, we performed a retro-
spective analysis on the use of continuous-ﬂow (CF)-
LVADs comparing 23 patients from 65 to 72 years of
age with 47 heart transplant recipients in the same age
group (36). Those patients selected for LVAD as DT
were slightly older and had greater hemodynamic
impairment than those who were transplanted.
Despite these differences, the 2-year survival rates
post-LVAD or -transplant were comparable. Whether
the long-term outcomes would be similar is unknown.
The choice of the ideal therapy for these patients
needs to be studied in a prospective trial.
Statistical survival models that include both BTT
and DT LVAD have also been developed. TheModel for
End Stage Liver Disease (MELD) has been used to
prognosticate the risk of patients with cirrhosis un-
dergoing shunt placement and is currently used to risk
stratify patients for liver transplant. This formula in-
cludes the log transformation of serum creatinine,
bilirubin, and prothrombin time international nor-
malized ratio (INR). MELD scores >17 were associated
with increased risk for perioperative bleeding and
mortality in DT and BTT LVAD patients (37,38). In an
analysis of the HeartMate II registry, maintained
by Thoratec, Inc. (Pleasanton, California), age, serum
albumin, creatinine, INR, and center volume of
LVAD surgeries were the strongest parameters indetermining 90-day mortality. A HeartMate II Risk
Score was derived. Patients were risk stratiﬁed by the
scores, with a low risk score <1.58 and a high risk score
>2.48, using the following equation (0.0274  [age in
years])  (0.723  albumin g/dl) þ (0.74  creatinine
mg/dl) þ (1.136  INR) þ (0.807  1 if LVAD volume <15
and 0 if LVAD volume >15) (39). However, subsequent
analysis questioned the reproducibility of such scores
in discriminating outcomes in high-volume centers (40).
Analysis of the INTERMACS data has provided in-
sights as to characteristics of DT patients who have
survival comparable to transplant outcomes. Of the
1,287 DT candidates analyzed from June 2006 to
December 2011, of whom 1,160 received CF-LVADs
and 128 received pulsatile pumps, 112 patients who
were not INTERMACs Level 1, had no prior history
of cancer, no previous cardiovascular surgery, and
blood urea nitrogen <50 mg/dl comprised the low-
risk patients with 1- and 2-year survival of 88%
and 80%, respectively. Risk factors for increased
mortality included: older age (>75 years), elevated
body mass index (>32 kg/m2), history of malig-
nancy, history of cardiac surgery, cardiogenic shock
(INTERMACS level 1), dialysis, renal insufﬁciency
(blood urea nitrogen >50 mg/dl), and use of a pulsa-
tile device or a right ventricular assist device (41).
Further risk stratiﬁcation could conceivably be per-
formed to identify subsets of patients who would
have survival comparable to transplant, thus helping
to decompress the ever-lengthening cardiac trans-
plant recipient waitlist.
With the continued expansion of LVAD therapy as
a BTT and DT, cardiac transplantation may eventually
become the future bailout strategy for device patients
who develop complications. Analysis of United
Network of Organ Sharing data already shows a shift
in the allocation of organs to more Status 1A patients
with device complications (42). The greater numbers
of BTT listed as United Network of Organ Sharing 1A
due to device malfunction, thrombosis, and infection
may negatively affect the current excellent long-term
transplant outcomes. In this study, however, infected
ventricular assist device patients had signiﬁcantly
lower 1-year post-transplant survival.
LVAD AS DESTINATION
MORTALITY. Most current long-term LVADs have
been tested initially as BTT in transplant candidates.
Only recently, as devices became more durable,
portable, and user-friendly, has this practice pattern
begun to evolve toward DT (7–9,19,43–45). Table 2
summarizes the major clinical trials assessing sur-
vival on long-term LVADs.
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2547The REMATCH study, published in 2001 (19), was
the landmark trial that established the beneﬁt of
LVAD therapy in patients with Stage D HFrEF.
Although this trial demonstrated a prolongation in
survival, the durability and adverse event proﬁle of
the pulsatile HeartMate XVE was suboptimal. Subse-
quent trials using CF-LVADs have demonstrated
markedly improved 1-year survival (7–9). Expansion
of DT began after the January 2010 approval of the
HeartMate II LVAD by the FDA, and since 2012, the
number of DT implants has surpassed the number
of BTT implants. The number of total LVAD implants
for all categories is now greater than the number of
annual heart transplant procedures. As reported by
INTERMACS, 1-year survival of the 3,931 reported
destination LVAD patients from June 2006 to June
2014 was approximately 75%. However, the im-
provement in technology and medical expertise is
also clearly reﬂected in the superior survival data
over the years (Figure 2). The results of HeartMate II
post-approval study for DT patients showed 1-yearTABLE 2 Published LVAD Clinical Trials
Study, Year
(Ref. #) n
Device
Tested Indication Design
REMATCH,
2001 (19)
129 HeartMate
XVE
DT Prospective 1:1 HeartM
XVE vs. medical th
INTREPID,
2007 (43)
55 Novacor DT Prospective nonrando
HeartMate II,
2009 (7)
192 HeartMate II DT Prospective randomiz
2:1 HeartMate II v
HeartMate XVE
HeartMate II
post-approval,
2014 (45)
247 HeartMate II DT Prospective nonrando
HeartMate II,
2007 (8)
133 HeartMate II BTT Prospective nonrando
HeartMate II
post-approval,
2011 (44)
169 HeartMate II BTT Prospective nonrando
ADVANCE,
2012 (9)
137 HVAD BTT Prospective nonrando
HVAD compared w
499 patients who
FDA-approved LVA
INTERMACS
ADVANCE ¼ Evaluation of HeartWare ventricular Assist Device for the Treatment of Adv
HVAD ¼ HeartWare Ventricular Assist Device; INTERMACS ¼ Interagency Registry for Mec
Dependent; LVAD ¼ left ventricular assist device; REMATCH ¼ Randomized Evaluationsurvival of 82% in INTERMACS proﬁles 4 to 7
(not inotrope-dependent) versus 72% for proﬁles 1 to
3 (inotrope-dependent). This survival was signiﬁ-
cantly lower than the 88% 1-year survival for the
2,843 BTT patients, but this is not unexpected given
the younger age of the BTT subjects and their fewer
signiﬁcant comorbidities (45,46). Currently, 80% of
approved device implants as BTT or DT are for pa-
tients in INTERMACS levels 1 to 3 (Figure 1). The
ROADMAP (Risk Assessment and Comparative Effec-
tiveness of Left Ventricular Assist Device and Medical
Management in Ambulatory Heart Failure Patients)
study is a prospective, multicenter, nonrandomized,
observational study that examined the outcome of
200 nontransplant-eligible patients with NYHA func-
tional class IIIB to IV chronic HF not on parenteral
inotropic therapy (INTERMACS levels 4 to 7), with a
left ventricular ejection fraction #25%, and a 6-min
walk distance <300 meters (47,48). The results, just
presented at the International Society of Heart Lung
Transplant 2015 meeting, show a similar mortality ofPatient Population Outcome
ate
erapy
New York Heart Association functional
class IV for 60 days, LVEF <25%, and
peak oxygen consumption<14 ml/min/kg
(unless on balloon pump, intravenous
inotropes, or physically unable to
perform exercise test), or intra-aortic
balloon pump or IV inotrope
dependent for 14 days
1- and 2-yr HeartMate XVE survival of
52% and 23% vs. 25% and 8% on
medical therapy
mized Inotrope-dependent patients 1-yr Novacor survival of 27% vs. 11% on
medical therapy
ed
s.
New York Heart Association functional
class IIIB or IV symptoms for >45 of the
last 60 days, LVEF <25%, and peak
oxygen consumption <14 ml/min/kg
(unless on balloon pump, intravenous
inotropes, or physically unable to
perform exercise test), or intra-aortic
balloon pump dependent for 7 days or
IV inotrope dependent for 14 days
1- and 2-yr HeartMate II survival of 68%
and 58% vs. 55% and 24% with
HeartMate XVE
mized Consecutive patients eligible for
destination DT in INTERMACS
1- and 2-yr survival of 74% and 61%
mized Transplant candidates 75% survival to transplant, recovery, or
ongoing support although remaining
eligible for transplant at 6 months
mized Consecutive patients eligible for
transplant in INTERMACS
90% survival to transplant, recovery, or
ongoing support at 6 months
mized.
ith
received
Ds in
Transplant candidates 90.7% survival to transplant, recovery,
or ongoing support on the original
device vs. 90.1% in control group at
6 months
anced Heart Failure; BTT ¼ bridge to transplant; DT ¼ destination therapy; FDA ¼ Food and Drug Administration;
hanical Assisted Circulatory Support; INTREPID ¼ Investigation of Non Transplant Eligible Patients Who Are Inotrope
of Mechanical Assistance for Treatment of Heart Failure.
FIGURE 2 Survival Curves in Stage D HF Patients Following Different Treatment
Modalities
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2548w20% in the HeartMate II LVAD and medical arms,
but improved functional capacity and quality of life
in the LVAD arm at 1 year. However, signiﬁcant
adverse events were much more frequent in the
device-supported group versus the medical arm,
including bleeding, stroke, ventricular arrhythmias,
and rehospitalizations, in addition to problems with
pump thrombosis and driveline infections. Of note,
22% of patients in the medical arm transitioned to
delayed LVAD placement at 1 year. On the basis of
these results, it appears that patients and their physi-
cians may have to weigh the beneﬁt of overall
improved functional capacity and quality of life
against a real risk of adverse events requiring hospi-
talizations while on LVAD support, which, in the end,
may become inevitable for patients who will fail
medicalmanagement. Cost-effectiveness of DTmay be
questioned, with the need for more medical resources
on top of the already expensive device implant, hos-
pitalization, and costs for long-term equipment.
ROADMAP is a hypothesis-generating study.
REVIVE-IT (Randomized Evaluation of VAD Inter-
VEntion before Inotropic Therapy) was a National
Heart, Lung, and Blood Institute (NHLBI)-sponsored
prospective, randomized trial for the evaluation of
HeartMate II LVAD as DT intervention in NYHAfunctional class III chronic HF before inotropic ther-
apy (49). However, the data and safety monitoring
board recommended that the National Heart, Lung,
and Blood Institute closed the study due to lack of
clinical equipoise.
MORBIDITY. Despite the improved survival, there
continue to be frequent long-term complications
associated with CF-LVADs. The post-approval Heart-
Mate II DT study reported a high probability of device-
related adverse events in patients at 2-year follow-up:
driveline infections (19%), sepsis (19%), strokes
(11.7%), thrombus formation (3.6%), bleeding (54%),
mechanical failures requiring replacement (4%), and
right HF (18%) (45). In addition, acquired von Wille-
brand’s disease rapidly develops in virtually all pa-
tients post–CF-LVAD implant (50). Aortic insufﬁciency
is also frequent, with an incidence of >30% at 3 years
(51). A report of an increased rate of pump thrombosis
since 2011 has been published (52). The etiology for
this observation is unclear, and it is likely a multifac-
torial process that might have resulted from less
frequent use of perioperative heparin, lower target
INR ranges due to the high incidence of bleeding,
inadequate antiplatelet therapy, overestimation of
effective anticoagulation by the partial prothrombin
time, abnormal angulation of inﬂow or outﬂow can-
nulas, infections, use of erythropoietic factors, and/or
other factors not yet identiﬁed (50,52–55).
The event rate in device-supported patients
resulting in rehospitalization for infection, bleeding,
device malfunction, stroke, or death is extremely
high, at 70% in the ﬁrst year (46). The recent ROAD-
MAP study conﬁrmed a high incidence of adverse
events even in “less sick” patients (see earlier dis-
cussion) (48). Thus, ongoing research is needed to
develop newer and improved devices.
EVOLUTION OF LVAD TECHNOLOGY
PAST AND PRESENT. The rapid evolution of me-
chanical circulatory support for the treatment of
advancedHFrEF has been remarkable. In 1969, theﬁrst
total artiﬁcial heart was implanted. However, several
issues hampered the expansion of total artiﬁcial heart
technology. Limited durability, an excessive rate of
complications, the risk of sudden device interruption
and death, and elimination of the possibility of native
cardiac recovery limited its use to severe biventricular
failure (i.e., CardioWest, SynCardia, Tucson, Arizona)
and shifted the focus to the development of
LVAD technology (Figure 3). First-generation volume
displacement LVADs used a diaphragm and unidirec-
tional valves to replicate the pulsatile cardiac cycle
through diastolic ﬁlling and systolic emptying of the
FIGURE 3 Schematic of an LVAD System
Components include a surgically implanted pump that works in parallel with the native heart via an inﬂow cannula to the left ventricle and an
outﬂow graft to the ascending aorta, a percutaneous driveline, a system controller and electrically powered batteries with a life span up to 12 h
(A). Features of continuous-ﬂow axial (B), centrifugal (C), and mixed design pumps, where the pump is axial but blood exits perpendicular to
the inﬂow like in centrifugal pumps (D), are also shown.
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2549device. The results of the REMATCH trial (19) led to
FDA approval of the HeartMate XVE for DT in 2002.
However, despite these results, ﬁrst-generation pul-
satile pumps were not widely used, with only 119 DT
implants in 2003, rising to 377 in 2005. Physicians and
patients had concerns regarding the large pump size,
adverse events, and limited durability, with uniform
failure after 18 to 30 months of support. HeartMate
XVE production has been discontinued.
Over the past 2 decades, CF-LVAD technology has
quickly developed, primarily due to its durability and
the miniaturization of pump size. Contemporary sec-
ond- and third-generation LVADs are valveless pumps
that utilize a permanent magnetic ﬁeld designed torapidly spin a single impeller supported by mechani-
cal or, more recently, hydrodynamic or magnetic
bearings (Table 3). Second-generation axial pumps
have the impeller outﬂow directed parallel to the axis
of rotation. The rotor spins on mechanical (HeartMate
II, Jarvik 2000 [Jarvik Heart, New York, New York],
and HeartAssist 5 [ReliantHeart, Houston, Texas])
or contact-free bearings (Incor, Berlin Heart, Berlin,
Germany). Third-generation centrifugal pumps have
the impeller outﬂow directed perpendicular from the
axis of rotation (HeartWare Ventricular Assist Device
[HVAD] [HeartWare, Framingham, Massachusetts]
and HeartMate III). Other pumps use a mixed design,
where blood ﬂow follows the axis of rotation but exits
TABLE 3 Contemporary Continuous-Flow LVADs
Device Manufacturer Design Bearings
Intermittent
Lower Speed
Operation
(Pulsatility) Position
Weight
(g)
Maximal
Flow
(l/min) Special Features Trials FDA Approval
HeartMate II Thoratec Axial Mechanical No Pre-peritoneal or
intra-abdominal
281 10 >10 yrs of experience BTT and DT trials completed
in the United States,
results published
(8,19,44,45)
BTT 2008; DT 2010
Jarvik 2000 Jarvik Heart Axial Mechanical Yes Pericardial 90 7 Minimally-invasive option
with outﬂow graft to
descending aorta;
post-auricular driveline
(<infection); low-speed
operation (8 s/min)
allowing aortic valve
opening
Commercially available in
Europe; BTT completed in
the United States, results
not published;
DT ongoing in the United States
Investigational
Incor Berlin Heart Axial Hydrodynamic No Pericardial 200 8 Commercially available in
Europe; no ongoing trials
in the United States
Investigational
HeartAssist 5 ReliantHeart Axial Mechanical No Pericardial 92 10 Direct ﬂow measurement;
remote monitoring and
device interrogation
akin to pacemakers and
deﬁbrillators
Commercially available in
Europe; BTT trial in the
United States expected
to start in 2015
Investigational
HVAD HeartWare Centrifugal Hydrodynamic No Pericardial 145 10 >5 yrs experience BTT trial completed in the
United States, results
published (9); DT trial
completed; supplemental
cohort ongoing in the
United States
BTT 2012
HeartMate III Thoratec Centrifugal Magnetic Yes Pericardial 200 10 Pump speed modulation:
antithrombotic cycling
(washout) and >pulsatility
Feasibility trial ongoing
in the United States
Investigational
MVAD HeartWare Mixed Hydrodynamic Yes Pericardial 92 6.5 Pump speed modulation:
antithrombotic cycling
(washout) and >pulsatility.
Potential biventricular
support
Feasibility trial expected
to start in Europe in 2015
Investigational
HVAD ¼ HeartWare Ventricular Assist Device; MVAD ¼ miniature ventricular assist device; other abbreviations as in Table 2.
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2551perpendicular to the inﬂow (miniature ventricular
assist device [MVAD] [HeartWare]). The design
of most recent pumps is contact-free, with no me-
chanical bearings and an impeller suspended using
magnetic and/or hydrodynamic systems. One con-
sideration in avoiding mechanical bearings is that
formation of a small thrombus on the metal could lead
to overheating and propagation of the thrombus.
Hydrodynamic levitation, in contact-free systems,
uses a layer of blood (blood bearing) to lift the rotor
(Incor, HVAD, and MVAD). Full magnetic levitation
utilizes magnetic bearings only to levitate the rotor
(HeartMate III). Avoiding hydrodynamic bearings
may reduce the risk that small pieces of foreign
matter, such as a thrombus, disrupt the opera-
tion of the rotor, leading to additional thrombus
formation and pump dysfunction.
In CF-LVADs, pump blood ﬂow is directly propor-
tional to rotor speed and inversely proportional to the
pressure differential between the left ventricle and
aorta. However, axial and centrifugal pumps differ in
their hydrodynamic performance, as characterized by
the relation between ﬂow rate and head pressure (the
pressure gradient across the pump, i.e., the differ-
ential pressure between the inlet in the left ventricle
and the outlet in the aorta) (Figure 4) (56,57). Axial
ﬂow pumps show a steep and inverse linear rela-
tionship between ﬂow and head pressure. In contrast,
this relationship is ﬂatter and more susceptible
to head pressure changes (i.e., more sensitive toFIGURE 4 Relationship Between Head Pressure and LVAD Flow in A
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Modiﬁed with permission from Pagani (56). AoP ¼ mean aortic pressure
ventricular pressure; P ¼ pressure; Q ¼ ﬂow.pre-load and afterload) in centrifugal pumps. With
the same change in pressure, centrifugal pumps
generate larger changes in ﬂow, ranging from 0 to 10
l/min, whereas the axial ﬂow pump ﬂow ranges from
3 to 7 l/min (Figure 4). These hydrodynamic charac-
teristics of centrifugal pumps translate into: 1) a more
pulsatile waveform; 2) a more accurate ﬂow estima-
tion; and 3) a lower risk of suction events (e.g., in a
setting of dehydration, arrhythmias, or right ven-
tricular failure); but also 4) more dependency of
device ﬂow on loading conditions when compared
with axial ﬂow pumps (56–58).
FUTURE DIRECTIONS. Pulsatility, further miniaturi-
zation, total implantability and remote monitoring
dominate current trends in the evolving technology
of present-day LVADs.
Pulsat i l i ty . Complications related to aortic valve
insufﬁciency, gastrointestinal bleeding, pump throm-
bosis, and stroke have hampered long-term results
and thereby limited the expansion of LVAD technol-
ogy. Low arterial pulsatility has been implicated
in the development of several serious adverse effects
of CF-LVADs. For example, persistently diminished
pulse pressure may contribute to the development of
arteriovenousmalformations (58), and continuous left
ventricle unloading decreases the frequency of aortic
valve opening, promoting commissural fusion and,
ultimately, aortic insufﬁciency (51,59). Additionally, a
closed aortic valve predisposes to stasis and clot for-
mation above the closed valve. Thus, recent researchxial and Centrifugal Pumps and the Effect on Pulsatility
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2552has focused on methods to generate more pulsatility
and (intermittent) aortic valve opening. This can be
achieved using pump speed modulation (i.e., inter-
mittent lower-speed pump operation) that: 1) gener-
ates intrinsic pulsatile ﬂow from the LVAD itself; and/
or 2) allows the native left ventricle to periodicallyFIGURE 5 Hemodynamic Curves Without and With HVAD Support
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2553modulation can be programmed to deliver maxi-
mum LVAD ﬂow during left ventricle systole (cop-
ulsation) or during diastole (counterpulsation)
(60,61). Counterpulsation maximizes left ventricle
unloading, thereby providing the best resting condi-
tions for the failing heart. Copulsation enhances
pulse pressure but decreases the likelihood of aortic
valve opening, because LVAD ﬂow, and thereby arte-
rial pressure, increases during cardiac systole (62).
Asynchronous mode offers the advantage of not
requiring a triggering source and theoretically com-
bines the physiological beneﬁts of intermittent
copulse-counterpulse support (Figure 5) (61).
Additionally, LVAD speed modulation can be
used for antithrombotic cycling to prevent pump
thrombosis, one of the most feared and life-
threatening complications, by precluding the forma-
tion of zones of recirculation and stasis within the
device (i.e., washout). In the future, speed modula-
tion algorithms might respond to speciﬁc physiolog-
ical demands, such as those related to exercise or
states of extreme hypertension or hypotension, ar-
rhythmias, baroreceptor signaling and/or hormonal
changes (63).
Miniatur izat ion . Smaller devices offer several po-
tential advantages such as: 1) minimally-invasive
surgery via a left thoracotomy without cardiopulmo-
nary bypass; 2) fewer size and sex limitations; and
3) potential for both left and right ventricular long-
term support, the latter of which has already been
described in several cases using HVADs (64), thus
preventing the need for a totally artiﬁcial heart in
severe biventricular failure.
Tota l implantab i l i ty . A fully-implantable system
that is rechargeable transcutaneously is an option
desired by patients. However, several technical
challenges remain. Two large discontinued pulsatile
systems, the AbioCor total artiﬁcial heart and the
LionHeart LVAD, used transcutaneous energy trans-
fer systems to transmit power across the skin. Theo-
retical advantages include: 1) the absence of driveline
exit site, which would eliminate driveline infections;
2) improved patient acceptance of LVAD therapy:
no driveline, ability to remove all externally worn
equipment for a period of time; 3) participation
in activities such as bathing and swimming, where
the body is completely submerged in water. Potential
disadvantages include: 1) risk of internal infection
of implanted material; 2) component failure or mi-
gration requiring elective (similar to a pacemaker or a
deﬁbrillator generator change) or emergent surgical
intervention; 3) bleeding risk and pain from all im-
planted components; 4) size and sex limitation due to
the large cumulative volume of all implanted parts.Time is needed to address these challenges and to
optimize a fully-implantable system before human
studies can resume.
Remote monitor ing . Akin to the advances seen in
deﬁbrillator and pacemaker therapy, remote device
monitoring is another future goal of LVAD technology.
The HeartAssist 5, which is currently being tested in
Europe, carries a “cell phone system” within the
controller that transmits ﬂow, power, and speed data
every 15 min. These LVAD parameters as well as alarm
notiﬁcations can be promptly delivered to health care
providers via text messages or e-mail.
LVAD THERAPY AND RECOVERY
Mechanical support results in profound volume
unloading in the left ventricle. This causes dramatic
reductions in ventricular size and shape, followed
by structural, biochemical, and genetic changes,
leading to a phenomenon called reverse remodeling.
There is a marked shift in the left ventricle end-
diastolic pressure–volume relationship toward nor-
mal. Some clinical reports have described a high rate
of myocardial recovery when coupled with high-dose
neurohormonal blockade and b-2 agonist therapy
with clenbuterol (65,66). Most studies in the United
States have not been able to reproduce these ﬁndings
and observe recovery rates <10%, although one
recent prospective trial at a single U.S. center re-
ported a 19% recovery rate with full neurohormonal
blockade (43,67–74). Yet, the potential for LVADs
to be used as a tool to rest the heart and, in these
settings, to test newer therapies that can reverse
myocardial dysfunction is very intriguing. A recent
clinical trial using intramyocardial injections of
mesenchymal stem cells at the time of LVAD surgery
reported a trend toward improved tolerability of
weaning from mechanical support (75).
CONCLUSIONS
LVADs represent a signiﬁcant advancement in the
ﬁeld of advanced HF. Device technology continues to
evolve rapidly. Patient survival is improving, despite
the many device-related complications. Future clin-
ical trials are needed to determine who would beneﬁt
most from device support versus cardiac trans-
plantation and whether LVAD support may favor
cardiac recovery.
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